Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.33 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887245 | 0.86 | AR (0.31) | — | |
| SCHEMBL5887144 | 0.85 | PTGS2 (0.34) | — | |
| SCHEMBL5887236 | 0.85 | ESR2 (0.35) | — | |
| SCHEMBL5887415 | 0.82 | AHR (0.38) | AHRALKBH3MAOBEGFRAKR1C2 | |
| SCHEMBL5887212 | 0.82 | ALKBH3 (0.39) | AHRALKBH3MAOBEGFRAKR1C2 | |
| SCHEMBL5887178 | 0.81 | AHR (0.31) | AHRALKBH3MAOB | |
| SCHEMBL5887332 | 0.81 | MRGPRX1 (0.31) | AHRALKBH3MAOBPDE3ASLC6A3 | |
| SCHEMBL5887450 | 0.81 | KIF11 (0.36) | CYP1B1 | |
| SCHEMBL5887446 | 0.80 | ALKBH3 (0.39) | AHRALKBH3MAOBEGFRAKR1C3 | |
| SCHEMBL5887017 | 0.80 | EGFR (0.38) | AHRALKBH3MAOBEGFRAKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | disclosed |
| US-20050026903-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | JONES TODD K (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | CCKAR, CCKBR, NPY1R | AHR 16/4885ALKBH3 3753/4885MAOB 1004/4885 |
| US-20050026903-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GLP1R | AHR 28/4885ALKBH3 3208/4885MAOB 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.